MOLECULAR ANALYSIS AND PROTEIN PROCESSING IN LATE-ONSET POMPE DISEASE PATIENTS WITH LOW LEVELS OF ACID α-GLUCOSIDASE ACTIVITY

被引:24
作者
Bali, Deeksha S. [1 ]
Tolun, Adviye A. [1 ]
Goldstein, Jennifer L. [1 ]
Dai, Jian [1 ]
Kishnani, Priya S. [1 ]
机构
[1] Duke Univ, Med Ctr, Dept Pediat, Div Med Genet, Durham, NC 27713 USA
关键词
acid alpha-glucosidase; cross-reactive immunological material; enzyme assay; GAA; Pompe disease; GENOTYPE-PHENOTYPE CORRELATION; GLYCOGENOSIS TYPE-II; ALGLUCOSIDASE ALPHA; MALTASE DEFICIENCY; HIGH-FREQUENCY; MUTATION; GENE; INFANTILE; JUVENILE; PSEUDODEFICIENCY;
D O I
10.1002/mus.21933
中图分类号
R74 [神经病学与精神病学];
学科分类号
摘要
Introduction: Pompe disease (glycogen storage disease type II, acid maltase deficiency) is caused by deficiency of lysosomal acid alpha-glucosidase (GAA). A few late-onset patients have been reported with skin fibroblast GAA activity levels of < 2%. Methods: We measured GAA activity in skin fibroblasts from 101 patients with late-onset Pompe disease. Whenever possible, we performed Western blot analysis and correlated the results with GAA activity and GAA gene mutations. Results: Thirteen patients (13%) had skin fibroblast GAA activity of < 1% of normal. Although there was wide genetic heterogeneity, none of these patients carried the common late-onset mutation c.-32-13T > G. We performed Western blot on 11 patients with < 1% GAA activity. All produced GAA protein that was at lower levels and/or was abnormally processed. Discussion: There is no common mutation associated with < 1% GAA activity in late-onset Pompe disease patients. Most patients produce unprocessed forms of GAA protein compared with patients with higher GAA activity. Muscle Nerve 43: 665-670, 2011
引用
收藏
页码:665 / 670
页数:6
相关论文
共 51 条
[1]  
Adams EM, 1997, HUM MUTAT, V10, P128, DOI 10.1002/(SICI)1098-1004(1997)10:2<128::AID-HUMU5>3.3.CO
[2]  
2-S
[3]   Systemic correction of the muscle disorder glycogen storage disease type II after hepatic targeting of a modified adenovirus vector encoding human acid-α-glucosidase [J].
Amalfitano, A ;
McVie-Wylie, AJ ;
Hu, H ;
Dawson, TL ;
Raben, N ;
Plotz, P ;
Chen, YT .
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 1999, 96 (16) :8861-8866
[4]  
Beesley C E, 1998, Hum Mutat, V11, P413, DOI 10.1002/(SICI)1098-1004(1998)11:5<413::AID-HUMU16>3.0.CO
[5]  
2-I
[6]  
Chiara A, 2008, NEUROLOGY, V70, P617, DOI 10.1212/01.wnl.0000299892.81127.8e
[7]   Early detection of Pompe disease by newborn screening is feasible: Results from the Taiwan screening program [J].
Chien, Yin-Hsiu ;
Chiang, Shu-Chuan ;
Zhang, Xiaokui Kate ;
Keutzer, Joan ;
Lee, Ni-Chung ;
Huang, Ai-Chu ;
Chen, Chun-An ;
Wu, Mei-Hwan ;
Huang, Pei-Hsin ;
Tsai, Fu-Jen ;
Chen, Yuan-Tsong ;
Hwu, Wuh-Liang .
PEDIATRICS, 2008, 122 (01) :E39-E45
[8]   Pompe Disease in Infants: Improving the Prognosis by Newborn Screening and Early Treatment [J].
Chien, Yin-Hsiu ;
Lee, Ni-Chung ;
Thurberg, Beth L. ;
Chiang, Shu-Chuan ;
Zhang, Xiaokui Kate ;
Keutzer, Joan ;
Huang, Ai-Chu ;
Wu, Mei-Hwan ;
Huang, Pei-Hsin ;
Tsai, Fuu-Jen ;
Chen, Yuan-Tsong ;
Hwu, Wuh-Liang .
PEDIATRICS, 2009, 124 (06) :E1116-E1125
[9]   Glycogen storage disease type II in Spanish patients:: High frequency of c.1076-1G&gt;C mutation [J].
Gort, Laura ;
Coll, M. Josep ;
Chabas, Amparo .
MOLECULAR GENETICS AND METABOLISM, 2007, 92 (1-2) :183-187
[10]   THE CONSERVATIVE SUBSTITUTION ASP-645-]GLU IN LYSOSOMAL ALPHA-GLUCOSIDASE AFFECTS TRANSPORT AND PHOSPHORYLATION OF THE ENZYME IN AN ADULT PATIENT WITH GLYCOGEN-STORAGE-DISEASE TYPE-II [J].
HERMANS, MMP ;
DEGRAAFF, E ;
KROOS, MA ;
WISSELAAR, HA ;
WILLEMSEN, R ;
OOSTRA, BA ;
REUSER, AJJ .
BIOCHEMICAL JOURNAL, 1993, 289 :687-693